Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia

[1]  E. Weiller,et al.  Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies , 2016, Schizophrenia Research.

[2]  J. Kane,et al.  Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial , 2015, Journal of clinical psychopharmacology.

[3]  J. Kane,et al.  A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia , 2015, Schizophrenia Research.

[4]  C. Correll,et al.  Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial. , 2015, The American journal of psychiatry.

[5]  G. Dunn,et al.  Validity of subjective versus objective quality of life assessment in people with schizophrenia , 2014, BMC Psychiatry.

[6]  C. Bundgaard,et al.  Brexpiprazole II: Antipsychotic-Like and Procognitive Effects of a Novel Serotonin-Dopamine Activity Modulator , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[7]  Tine Bryan Stensbøl,et al.  Brexpiprazole I: In Vitro and In Vivo Characterization of a Novel Serotonin-Dopamine Activity Modulator , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[8]  C. Luckhaus,et al.  5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis. , 2014, The international journal of neuropsychopharmacology.

[9]  Dimitris Mavridis,et al.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis , 2013, The Lancet.

[10]  L. Citrome.  A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach , 2013, CNS Drugs.

[11]  Marc De Hert,et al.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs , 2012, Nature Reviews Endocrinology.

[12]  Barbara Stanley,et al.  The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. , 2011, The American journal of psychiatry.

[13]  H. El-sayeh,et al.  Aripiprazole versus placebo for schizophrenia. , 2011, The Cochrane database of systematic reviews.

[14]  S. Leucht,et al.  Clozapine versus other atypical antipsychotics for schizophrenia. , 2010, The Cochrane database of systematic reviews.

[15]  G. Sachs,et al.  Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials , 2010, Journal of psychopharmacology.

[16]  C. Correll.  From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics , 2010, European Psychiatry.

[17]  John M. Davis,et al.  Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. , 2010, Schizophrenia bulletin.

[18]  J. Volavka,et al.  Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making , 2009, Expert opinion on pharmacotherapy.

[19]  R. Perlis,et al.  Akathisia: an updated review focusing on second-generation antipsychotics. , 2009, The Journal of clinical psychiatry.

[20]  M. Brecher,et al.  Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. , 2007, The Journal of clinical psychiatry.

[21]  R. Mcquade,et al.  Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine , 2006, Psychopharmacology.

[22]  J. McGrath,et al.  A Systematic Review of the Prevalence of Schizophrenia , 2005, PLoS medicine.

[23]  P. Cowen,et al.  Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. , 2005, The Journal of clinical psychiatry.

[24]  R. Mcquade,et al.  A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. , 2004, The Journal of clinical psychiatry.

[25]  Del D. Miller.  Atypical antipsychotics: sleep, sedation, and efficacy. , 2004, Primary care companion to the Journal of clinical psychiatry.

[26]  S. Kapur,et al.  Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.

[27]  M. Clarke,et al.  Determinants of quality of life at first presentation with schizophrenia. , 2000, The British journal of psychiatry : the journal of mental science.

[28]  T. Barnes.  A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.

[29]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[30]  C. Luckhaus,et al.  5-HT 2 A receptor antagonists for the treatment of neuroleptic-induced akathisia : a systematic review and meta-analysis , 2014 .

[31]  S. Leucht,et al.  Quetiapine versus other atypical antipsychotics for schizophrenia. , 2010, The Cochrane database of systematic reviews.